Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-11-16

FDA Approved: RUFINAMIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved Lupin Pharmaceuticals' supplemental application for Rufinamide (generic), expanding its regulatory status for the treatment of Lennox-Gastaut s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rufinamide (Rufinamide)

Snippet

SUPPL AP for RUFINAMIDE (RUFINAMIDE)